Histidine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Histidine: From No Documented Indication to Gastroparesis
One-Sentence Summary
Histidine is an essential amino acid with no approved therapeutic indication on record in this evidence pack, and it is not currently marketed in South Africa. The TxGNN model predicts it may be effective for Gastroparesis, but this prediction is currently supported by zero clinical trials and zero published literature — it is a pure computational signal with no direct evidence behind it yet.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indication on record (Histidine is not currently marketed as a therapeutic product in South Africa) |
| Predicted New Indication | Gastroparesis (disease) |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L5 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Histidine is not currently available in this evidence pack, and no original approved indication is on file to anchor a comparison. Histidine is a precursor of histamine via the enzyme histidine decarboxylase (HDC), and the working hypothesis behind this prediction is that histidine could theoretically influence gastrointestinal motility and autonomic nervous system function through histamine-mediated signalling pathways relevant to gastric emptying.
However, this mechanistic link is speculative rather than evidence-based: there are no clinical trials, no literature, and no preclinical studies connecting Histidine specifically to Gastroparesis in this evidence pack. The prediction rests entirely on the TxGNN knowledge-graph embedding score, without any corroborating experimental or clinical signal.
It is worth noting that other, lower-ranked candidates in this evidence pack — particularly Dyspepsia (rank 6) — carry comparatively stronger supporting evidence (L4, decision stage S1, “Research Question”), including a human RCT/crossover study showing histidine-containing amino acid combinations affect gastric emptying and glucose metabolism. That candidate may warrant closer follow-up alongside or instead of Gastroparesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Histidine is not currently marketed in South Africa, and there are no SAHPRA product registrations on record for this substance in this evidence pack.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top-ranked predicted indication (Gastroparesis) has no supporting clinical trials or literature — it is a model-only (L5) prediction with no original indication, no MOA data, and no South African market presence to anchor a repurposing case.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (PI), including warnings/precautions and contraindications (flagged as a Blocking data gap — required before any safety pre-assessment can proceed)
- Documented mechanism of action (MOA) data from DrugBank or equivalent source
- A confirmed original/approved indication for Histidine to establish a baseline for repurposing comparison
- Targeted literature and clinical trial search specifically for “Histidine AND gastroparesis”
- Consideration of Dyspepsia (rank 6) as a secondary candidate, given its comparatively stronger mechanistic and human-study evidence (L4, S1)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.